Attovia Raises $90 Million in Series C Funding

Attovia Therapeutics has closed a $90 million Series C funding round, led by Deep Track Capital and supported by both new and existing investors, to advance its lead candidates, ATTO-1310 and ATTO-3712, through clinical proof-of-concept trials targeting chronic pruritus and atopic dermatitis. The financing will also support the expansion of Attovia's pipeline using its proprietary ATTOBODY technology, designed for enhanced potency and flexibility in developing treatments for immune-mediated disorders such as inflammatory bowel disease. ATTO-1310, a first-in-class anti-IL31 biologic, is currently in phase 1 trials for chronic pruritus of unknown origin, a condition with significant unmet medical need. Attovia's ATTOBODY platform enables the engineering of 'biparatopic' nanobodies that bind two epitopes simultaneously, potentially offering best-in-class efficacy. Company leadership highlighted the oversubscription of the round as evidence of strong investor confidence in the platform and team, emphasizing a multi-year runway to advance programs and explore strategic partnerships. The broader biotech fundraising environment remains challenging, making Attovia's success noteworthy within the industry.